Super Generics Market

Super Generics Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Therapeutic Area (Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), Route of Administration (Intravenous, Oral, Subcutaneous and Others), Type of Molecule (Small and Other Molecules), Type of Small Molecule (Generics and Other Small Molecules), Type of Product (Aerosols, Capsules, Prefilled Syringes, Tablets, Vials and Other Products) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    234

  • Pages
    257

  • View Count
    13692

Table Of Contents

1. PREFACE
1.1 Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations

2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Generic Drugs
5.2.1. Key Challenges within the Generics Industry
5.2.1.1. Policy Changes
5.2.1.2. Increasing Competition
5.2.1.3. Price Erosion

5.3. Super Generics
5.3.1. Techniques Used for the Development of Super Generics
5.3.2. Regulatory Pathways for Approval of Super Generics

5.4. Advantages of Super Generics
5.4.1. Improved Efficacy
5.4.2. Increased IP Protection
5.4.3. Cost and Time Efficient Development Process

5.5. Challenges Related to Super Generics
5.6. Future Perspectives

6. SUPER GENERIC DRUGS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Super Generic Drugs: Overall Market Landscape
6.2.1. Analysis by Route of Administration
6.2.2. Analysis by Target Indication
6.2.3. Analysis by Target Therapeutic Area
6.2.4. Analysis by Submission Classification Code
6.2.5. Most Active Players: Analysis by Number of Super Generic Drugs

7. SUPER GENERIC TECHNOLOGIES: MARKET LANDSCAPE
7.1 Chapter Overview
7.2. Super Generic Technologies: Overall Market Landscape
7.2.1 Analysis by Type of Drug Modification
7.2.2 Analysis by Type of Technology
7.2.3 Analysis by Type of Molecules Formulated / Delivered
7.2.4 Analysis by Route of Administration
7.2.5 Analysis by Type of Value Addition

7.3. Super Generics Technology Developers
7.3.1 Analysis by Year of Establishment
7.3.2 Analysis by Company Size
7.3.3 Analysis by Location of Headquarters (Region)
7.3.4. Most Active Players: Analysis by Number of Super Generics Technologies

8. TECHNOLOGY COMPETITIVENSS ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Technologies Offered by Companies based in North America
8.3.1 Technologies Offered by Companies based in North America (Peer Group I)
8.3.2 Technologies Offered by Companies based in North America (Peer Group II)
8.4 Technologies Offered by Companies based in Europe
8.5. Technologies Offered by Companies based in Asia-Pacific

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Ascendia Pharmaceuticals
9.2.1. Company Overview
9.2.2. Technology Portfolio
9.2.2.1. NanoSol
9.2.2.2. AmorSol
9.2.2.3. EmulSol

9.2.3. Recent Developments and Future Outlook

9.3. CritiTech
9.3.1. Company Overview
9.3.2. Technology Portfolio
9.3.2.1. Spray Drying Technology
9.3.2.2. Supercritical Precipitation Technology

9.3.3. Recent Developments and Future Outlook

9.4. Crossject
9.4.1. Company Overview
9.4.2. Technology Portfolio
9.4.2.1. ZENEO®

9.4.3. Recent Developments and Future Outlook

9.5. DelSiTech
9.5.1. Company Overview
9.5.2. Technology Portfolio
9.5.2.1. DelSiTech™ Silica

9.5.3. Recent Developments and Future Outlook

9.6. Heron Therapeutics
9.6.1. Company Overview
9.6.2. Technology Portfolio
9.6.2.1. Biochronomer®

9.6.3. Recent Developments and Future Outlook

9.7. Latitude Pharmaceuticals
9.7.1. Company Overview
9.7.2. Technology Portfolio
9.7.2.1. Nano-E™
9.7.2.2. PG-Depot™
9.7.2.3. ARTSS™
9.7.2.4. RFAP™ Matrix
9.7.2.5. RTTS
9.7.2.6. 24H™
9.7.2.7. MiniSpheres
9.7.2.8. GelPatch

9.7.3. Recent Developments and Future Outlook

9.8. Mayne Pharma
9.8.1. Company Overview
9.8.2. Financial Information
9.8.3. Technology Portfolio
9.8.3.1. SUBA™
9.8.3.2. Cleantaste™
9.8.3.3. Pellet Technology

9.8.4. Recent Developments and Future Outlooks

9.9. Neurelis
9.9.1. Company Overview
9.9.2. Technology Portfolio
9.9.2.1. Intravail®
9.9.2.2. ProTek®
9.9.2.3. Hydrogel™

9.9.3. Recent Developments and Future Outlook

9.10. Rubicon Research
9.10.1. Company Overview
9.10.2. Technology Portfolio
9.10.2.1. RubiERT®
9.10.2.2. RubiDT®
9.10.2.3. RubiReten®
9.10.2.4. RubiSRL®

9.11. Taiwan Liposome Company
9.11.1. Company Overview
9.11.2. Financial Information
9.11.3. Technology Portfolio
9.11.3.1. BioSeizer®
9.11.3.2. NanoX™
9.11.3.3. Polymeric Micelle

9.11.4. Recent Developments and Future Outlook

9.12. tesa Labtec
9.12.1. Company Overview
9.12.2. Technology Portfolio
9.12.2.1. Transfilm®
9.12.2.2. Mucofilm®
9.12.2.3. Rapidfilm®

9.12.3. Recent Developments and Future Outlook

10 CASE STUDY: APPROVED SUPER GENERIC DRUGS
10.1. Chapter Overview
10.2. Austedo®
10.2.1. Overview
10.2.2. Originator Drug Overview
10.2.3. Value Proposition
10.2.4. Financial Information
10.2.5. Key Learnings

10.3. Abraxane®
10.3.1. Overview
10.3.2. Originator Drug Overview
10.3.3. Value Proposition
10.3.4. Financial Information
10.3.5. Key Learnings

10.4. Avycaz®
10.4.1. Overview
10.4.2. Originator Drug Overview
10.4.3. Value Proposition
10.4.4. Financial Information
10.4.5. Key Learnings

10.5. Procysbi®
10.5.1. Overview
10.5.2. Originator Drug Overview
10.5.3. Value Proposition
10.5.4. Financial Information
10.5.5. Key Learnings

10.6. Trokendi XR®
10.6.1. Overview
10.6.2. Originator Drug Overview
10.6.3. Value Proposition
10.6.4. Financial Information
10.6.5. Key Learnings

11. SUPER GENERICS: LIKELY DRUG CANDIDATES
11.1. Chapter Overview
11.2. Marketed Drug Candidates
11.2.1. Most Likely Drug Candidates for Super Generics
11.2.2. Likely Drug Candidates for Super Generics
11.2.3. Less Likely Drug Candidates for Super Generics
11.2.4. Least Likely Drug Candidates for Super Generics

12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weakness
12.4. Opportunities
12.5. Threats
12.6. Concluding Remarks

13. GLOBAL SUPER GENERICS MARKET
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Overall Super Generics Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.4. Super Generics Market: Distribution by Therapeutic Area, 2023-2035
13.5. Super Generics Market: Distribution by Route of Administration, 2023-2035
13.6. Super Generics Market: Distribution by Type of Molecule, 2023-2035
13.7. Super Generics Market: Distribution by Type of Small Molecule, 2023-2035
13.8. Super Generics Market: Distribution by Type of Product, 2023-2035

13.9. Super Generics Market: Distribution by Geography, 2023-2035
13.9.1. Super Generics Market in North America, 2023-2035
13.9.1.1. Super Generics Market in North America: Distribution by Therapeutic Area, 2023-2035
13.9.1.1.1. Super Generics Market for Oncological Disorders in North America, 2023-2035
13.9.1.1.2. Super Generics Market for Metabolic Disorders in North America, 2023-2035
13.9.1.1.3. Super Generics Market for Neurological Disorders in North America, 2023-2035
13.9.1.1.4. Super Generics Market for Respiratory Disorders in North America, 2023-2035
13.9.1.1.5. Super Generics Market for Cardiovascular Disorders in North America, 2023-2035
13.9.1.1.6. Super Generics Market for Other Disorders in North America, 2023-2035

13.9.1.2. Super Generics Market: Distribution by Route of Administration in North America
13.9.1.2.1. Super Generics Market for Oral Route of Administration in North America, 2023-2035
13.9.12.2. Super Generics Market for Subcutaneous Route of Administration in North America, 2023-2035
13.9.1.2.3. Super Generics Market for Intravenous Route of Administration in North America, 2023-2035
13.9.1.2.4. Super Generics Market for Other Routes of Administration in North America, 2023-2035

13.9.1.3. Super Generics Market: Distribution by Type of Molecule in North America
13.9.1.3.1. Super Generics Market for Small Molecule in North America, 2023-2035
13.9.1.3.2. Super Generics Market for Biologics in North America, 2023-2035

13.9.1.4. Super Generics Market: Distribution by Type of Small Molecules in North America
13.9.1.4.1 Super Generics Market for Complex Generics in North America, 2023-2035
13.9.1.4.2. Super Generics Market for Other Small Molecules in North America, 2023-2035

13.9.1.5. Super Generics Market: Distribution by Type of Product Offered in North America
13.9.1.5.1. Super Generics Market for Prefilled Syringe in North America, 2023-2035
13.9.1.5.2. Super Generics Market for Vials in North America, 2023-2035
13.9.1.5.3. Super Generics Market for Aerosols in North America, 2023-2035
13.9.1.5.4. Super Generics Market for Tablets in North America, 2023-2035
13.9.1.5.5. Super Generics Market for Capsules in North America, 2023-2035
13.9.1.5.6. Super Generics Market for Other Types of Products in North America, 2023-2035

13.9.2. Super Generics Market in Europe, 2023-2035
13.9.2.1. Super Generics Market in Europe: Distribution by Therapeutic Area, 2023-2035
13.9.2.1.1. Super Generics Market for Oncological Disorders in Europe, 2023-2035
13.9.2.1.2. Super Generics Market for Metabolic Disorders in Europe, 2023-2035
13.9.2.1.3. Super Generics Market for Neurological Disorders in Europe, 2023-2035
13.9.2.1.4. Super Generics Market for Respiratory Disorders in Europe, 2023-2035
13.9.2.1.5. Super Generics Market for Cardiovascular Disorders in Europe, 2023-2035
13.9.2.1.6. Super Generics Market for Other Disorders in Europe, 2023-2035

13.9.2.2. Super Generics Market Distribution by Route of Administration in Europe
13.9.2.2.1. Super Generics Market for Oral Route of Administration in Europe, 2023-2035
13.9.2.2.2. Super Generics Market for Subcutaneous Route of Administration in Europe, 2023-2035
13.9.2.2.3. Super Generics Market for Intravenous Route of Administration in Europe, 2023-2035
13.9.2.2.4. Super Generics Market for Other Routes of Administration in Europe, 2023-2035

13.9.2.3. Super Generic Drugs Market: Distribution by Type of Molecule in Europe
13.9.2.3.1. Super Generic Drugs Market for Small Molecule in Europe, 2023-2035
13.9.2.3.2. Super Generic Drugs Market for Biologics in Europe, 2023-2035

13.9.2.4. Super Generic Drugs Market: Distribution by Type of Small Molecules in Europe
13.9.2.4.1 Super Generic Drugs Market for Complex Generics in Europe, 2023-2035
13.9.2.4.2. Super Generics Market for Other Small Molecules in Europe, 2023-2035

13.9.2.5. Super Generic Market: Distribution by Type of Product Offered in Europe
13.9.2.5.1. Super Generic Market for Prefilled Syringe in Europe, 2023-2035
13.9.2.5.2. Super Generic Market for Vials in Europe, 2023-2035
13.9.2.5.3. Super Generic Market for Aerosols in Europe, 2023-2035
13.9.2.5.4. Super Generic Market for Tablets in Europe, 2023-2035
13.9.2.5.5. Super Generic Market for Capsules in Europe, 2023-2035
13.9.2.5.6. Super Generics Market for Other Types of Products in Europe, 2023-2035

13.9.3. Super Generics Market in Asia-Pacific, 2023-2035
13.9.3.1. Super Generics Market in Asia-Pacific: Distribution by Therapeutic Area, 2023-2035
13.9.3.1.1. Super Generics Market for Oncological Disorders in Asia-Pacific, 2023-2035
13.9.3.1.2. Super Generics Market for Metabolic Disorders in Asia-Pacific, 2023-2035
13.9.3.1.3. Super Generics Market for Neurological Disorders in Asia-Pacific, 2023-2035
13.9.3.1.4. Super Generics Market for Respiratory Disorders in Asia-Pacific, 2023-2035
13.9.3.1.5. Super Generics Market for Cardiovascular Disorders in Asia-Pacific, 2023-2035
13.9.3.1.6. Super Generics Market for Other Disorders in Asia-Pacific, 2023-2035

13.9.3.2. Super Generics Market Distribution by Route of Administration in Asia-Pacific
13.9.3.2.1. Super Generics Market for Oral Route of Administration in Asia-Pacific, 2023-2035
13.9.3.2.2. Super Generics Market for Subcutaneous Route of Administration in Asia-Pacific, 2023-2035
13.9.3.2.3. Super Generics Market for Intravenous Route of Administration in Asia-Pacific, 2023-2035
13.9.4.2.4. Super Generics Market for Other Routes of Administration in Asia-Pacific, 2023-2035

13.9.3.3. Super Generics Market: Distribution by Type of Molecule in Asia-Pacific
13.9.3.3.1. Super Generics Market for Small Molecule in Asia-Pacific, 2023-2035
13.9.3.3.2. Super Generics Market for Biologics in Asia-Pacific, 2023-2035

13.9.3.4. Super Generics Market: Distribution by Type of Small Molecules in Asia-Pacific
13.9.3.4.1 Super Generics Market for Complex Generics in Asia-Pacific, 2023-2035
13.9.3.4.2. Super Generics Market for Other Small Molecules in Asia-Pacific, 2023-2035

13.9.3.5. Super Generics Market: Distribution by Type of Product Offered in Asia-Pacific
13.9.3.5.1. Super Generics Market for Prefilled Syringe in Asia-Pacific, 2023-2035
13.9.3.5.2. Super Generics Market for Vials in Asia-Pacific, 2023-2035
13.9.3.5.3. Super Generics Market for Aerosols in Asia-Pacific, 2023-2035
13.9.3.5.4. Super Generics Market for Tablets in Asia-Pacific, 2023-2035
13.9.3.5.5. Super Generics Market for Capsules in Asia-Pacific, 2023-2035
13.9.3.5.6. Super Generics Market for Other Types of Products in Asia-Pacific, 2023-2035

13.9.4. Super Generics Market in Rest of the World, 2023-2035
13.9.4.1. Super Generics Market in Rest of the World: Distribution by Therapeutic Area, 2023-2035
13.9.4.1.1. Super Generics Market for Oncological Disorders in Rest of the World, 2023-2035
13.9.4.1.2. Super Generics Market for Metabolic Disorders in Rest of the World, 2023-2035
13.9.4.1.3. Super Generics Market for Neurological Disorders in Rest of the World, 2023-2035
13.9.4.1.4. Super Generics Market for Respiratory Disorders in Rest of the World, 2023-2035
13.9.4.1.5. Super Generics Market for Cardiovascular Disorders in Rest of the World, 2023-2035
13.9.4.1.6. Super Generics Market for Other Disorders in Rest of the World, 2023-2035

13.9.4.2. Super Generics Market Distribution by Route of Administration in Rest of the World
13.9.4.2.1. Super Generics Market for Oral Route of Administration in Rest of the World, 2023-2035
13.9.4.2.2. Super Generics Market for Subcutaneous Route of Administration in Rest of the World, 2023-2035
13.9.4.2.3. Super Generics Market for Intravenous Route of Administration in Rest of the World, 2023-2035
13.9.4.2.4. Super Generics Market for Other Routes of Administration in Rest of the World, 2023-2035

13.9.4.3. Super Generics Market: Distribution by Type of Molecule in Rest of the World
13.9.4.3.1. Super Generics Market for Small Molecule in Rest of the World, 2023-2035
13.9.4.3.2. Super Generics Market for Biologics in Rest of the World, 2023-2035

13.9.4.4. Super Generics Market: Distribution by Type of Small Molecules in Rest of the World
13.9.4.4.1 Super Generics Market for Complex Generics in Rest of the World, 2023-2035
13.9.4.4.2. Super Generics Market for Other Small Molecules in Rest of the World, 2023-2035

13.9.4.5. Super Generics Market: Distribution by Type of Product Offered in Rest of the World
13.9.4.5.1. Super Generics Market for Prefilled Syringe in Rest of the World, 2023-2035
13.9.4.5.2. Super Generics Market for Vials in Rest of the World, 2023-2035
13.9.4.5.3. Super Generics Market for Aerosols in Rest of the World, 2023-2035
13.9.4.5.4. Super Generics Market for Tablets in Rest of the World, 2023-2035
13.9.4.5.5. Super Generics Market for Capsules in Rest of the World, 2023-2035
13.9.4.5.6. Super Generics Market for Other Types of Products in Rest of the World, 2023-2035

14. CONCLUSION

15. APPENDIX 1: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 5.1 Impact of Number of Drug Manufacturers on Price of Generic Drugs
Figure 5.2 Advantages Offered by Super Generics
Figure 5.3 Historical Drug Development Costs
Figure 6.1 Super Generic Drugs: Distribution by Route of Administration
Figure 6.2 Super Generic Drugs: Distribution by Target Indication
Figure 6.3 Super Generic Drugs: Distribution by Target Therapeutic Area
Figure 6.4 Super Generic Drugs: Distribution by Submission Classification Code
Figure 6.5 Most Active Players: Distribution by Number of Super Generic Drugs
Figure 7.1 Super Generic Technologies: Distribution by Type of Drug Modification
Figure 7.2 Super Generic Technologies: Distribution by Type of Technology
Figure 7.3 Super Generic Technologies: Distribution by Type of Molecules
Figure 7.4 Super Generic Technologies: Distribution by Route of Administration
Figure 7.5 Super Generic Technologies: Distribution by Type of Value Addition
Figure 7.6 Super Generic Technology Providers: Distribution by Year of Establishment
Figure 7.7 Super Generic Technology Providers: Distribution by Company Size
Figure 7.8. Super Generic Technology Providers: Distribution by Location of Headquarters (Region)
Figure 7.9. Most Active Players: Distribution by Number of Super Generic Technologies
Figure 8.1 Technology Competitiveness Analysis: Technologies Offered by Companies based in North America (Peer Group I)
Figure 8.2 Technology Competitiveness Analysis: Technologies Offered by Companies based in North America (Peer Group II)
Figure 8.3 Technology Competitiveness Analysis: Technologies Offered by Companies based in Europe
Figure 8.4 Technology Competitiveness Analysis: Technologies Offered by Companies based in Asia-Pacific
Figure 9.1 Ascendia Pharmaceuticals: Technology Portfolio
Figure 9.2 CritiTech: Technology Portfolio
Figure 9.3 Intellipharmaceutics International: Annual Revenues, 2013- H1 2019 (USD Million)
Figure 9.6 LATITUDE Pharmaceuticals: Technology Portfolio
Figure 9.7 Mayne Pharma: Annual Revenues, FY 2019-HI FY 2024 (USD Million)
Figure 9.8 Mayne Pharma: Technology Portfolio
Figure 9.9 Rubicon Research: Technology Portfolio
Figure 9.10. Taiwan Liposome Company: Annual Revenues, 2014-H1 2019 (NT$ Million)
Figure 9.11. Taiwan Liposome Company: Technology Portfolio
Figure 9.12. tesa Labtec: Technology Portfolio
Figure 10.1. Austedo®: Development Timeline
Figure 10.2. Revenue Comparison: Xenazine® versus Austedo® (USD Million)
Figure 10.3. Abraxane®: Development Timeline
Figure 10.4. Revenue Comparison: Taxol® versus Abraxane® (USD Million)
Figure 10.5. Annual Revenues: Abraxane® 2012-2018 (USD Million)
Figure 10.6. Avycaz®: Development Timeline
Figure 10.7. Annual Revenues: Avycaz® 2015-2018 (USD Million)
Figure 10.8 Procysbi®: Development Timeline
Figure 10.9. Annual Revenues: Procysbi® 2016-2018 (USD Million)
Figure 10.10. Trokendi XR®: Development Timeline
Figure 10.11 Annual Revenues: Trokendi XR® 2013-2018 (USD Million)
Figure 12.1 Super Generics: SWOT Analysis
Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1 Supergeneric Drugs Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035): Base Scenario (USD Billion)
Figure 13.2 Super Generics Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
Figure 13.3 Super Generics Market: Distribution by Route of Administration, 2023 and 2035 (USD Billion)
Figure 13.4 Super Generics Market: Distribution by Type of Molecule, 2023 and 2035 (USD Billion)
Figure 13.5 Super Generics Market: Distribution by Type of Small Molecule, 2023 and 2035 (USD Billion)
Figure 13.6 Super Generics Market: Distribution by Type of Product, 2023 and 2035 (USD Billion)
Figure 13.7 Super Generics Market: Distribution by Geography, 2023 and 2035 (USD Billion)
Figure 13.8 Supergeneric Drugs Market in North America, 2023-2035 (USD Billion)
Figure 13.9 Super Generics Market for Oncological Disorders in North America, 2023-2035 (USD Billion)
Figure 13.10 Super Generics Market for Metabolic Disorders in North America, 2023-2035 (USD Billion)
Figure 13.11 Super Generics Market for Neurological Disorders in North America, 2023-2035 (USD Billion)
Figure 13.12 Super Generics Market for Respiratory Disorders in North America, 2023-2035 (USD Billion) (USD Billion)
Figure 13.13 Super Generics Market for Cardiovascular Disorders in North America, 2023-2035 (USD Billion)
Figure 13.14 Super Generics Market for Other Disorders in North America, 2023-2035 (USD Billion)
Figure 13.15 Super Generics Market for Oral Route of Administration in North America, 2023-2035 (USD Billion)
Figure 13.16 Super Generics Market for Subcutaneous Route of Administration in North America, 2023-2035 (USD Billion)
Figure 13.17 Super Generics Market for Intravenous Route of Administration in North America, 2023-2035 (USD Billion)
Figure 13.18 Super Generics Market for Other Routes of Administration in North America, 2023-2035 (USD Billion)
Figure 13.19 Super Generics Market for Small Molecule in North America, 2023-2035 (USD Billion)
Figure 13.20 Super Generics Market for Biologics in North America, 2023-2035 (USD Billion)
Figure 13.21 Super Generics Market for Complex Generics in North America, 2023-2035 (USD Billion)
Figure 13.22 Super Generics Market for Other Small Molecules in North America, 2023-2035 (USD Billion)
Figure 13.23 Super Generics Market for Prefilled Syringe in North America, 2023-2035 (USD Billion)
Figure 13.24 Super Generics Market for Vials in North America, 2023-2035 (USD Billion)
Figure 13.25 Super Generics Market for Aerosols in North America, 2023-2035 (USD Billion)
Figure 13.26 Super Generics Market for Tablets in North America, 2023-2035 (USD Billion)
Figure 13.27 Super Generics Market for Capsules in North America, 2023-2035 (USD Billion)
Figure 13.28 Super Generics Market for Other Type of Products in North America, 2023-2035 (USD Billion)
Figure 13.29 Supergeneric Drugs Market in Europe, 2023-2035 (USD Billion)
Figure 13.30 Super Generics Market for Oncological Disorders in Europe, 2023-2035 (USD Billion)
Figure 13.31 Super Generics Market for Metabolic Disorders in Europe, 2023-2035 (USD Billion)
Figure 13.32 Super Generics Market for Neurological Disorders in Europe, 2023-2035 (USD Billion)
Figure 13.33 Super Generics Market for Respiratory Disorders in Europe, 2023-2035 (USD Billion)
Figure 13.34 Super Generics Market for Cardiovascular Disorders in Europe, 2023-2035 (USD Billion)
Figure 13.35 Super Generics Market for Other Disorders in Europe, 2023-2035 (USD Billion)
Figure 13.36 Super Generics Market for Oral Route of Administration in Europe, 2023-2035 (USD Billion)
Figure 13.37 Super Generics Market for Subcutaneous Route of Administration in Europe, 2023-2035 (USD Billion)
Figure 13.38 Super Generics Market for Intravenous Route of Administration in Europe, 2023-2035 (USD Billion)
Figure 13.39 Super Generics Market for Other Routes of Administration in Europe, 2023-2035 (USD Billion)
Figure 13.40 Super Generics Market for Small Molecule in Europe, 2023-2035 (USD Billion)
Figure 13.41 Super Generics Market for Biologics in Europe, 2023-2035 (USD Billion)
Figure 13.42 Super Generics Market for Complex Generics in Europe, 2023-2035 (USD Billion)
Figure 13.43 Super Generics Market for Other Small Molecules in Europe, 2023-2035 (USD Billion)
Figure 13.44 Super Generics Market for Prefilled Syringe in Europe, 2023-2035 (USD Billion)
Figure 13.45 Super Generics Market for Vials in Europe, 2023-2035 (USD Billion)
Figure 13.46 Super Generics Market for Aerosols in Europe, 2023-2035 (USD Billion)
Figure 13.47 Super Generics Market for Tablets in Europe, 2023-2035 (USD Billion)
Figure 13.48 Super Generics Market for Capsules in Europe, 2023-2035 (USD Billion)
Figure 13.49 Super Generics Market for Other Type of Products in Europe, 2023-2035 (USD Billion)
Figure 13.50 Supergeneric Drugs Market in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.51 Super Generics Market for Oncological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.52 Super Generics Market for Metabolic Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.53 Super Generics Market for Neurological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.54 Super Generics Market for Respiratory Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.55 Super Generics Market for Cardiovascular Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.56 Super Generics Market for Other Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.57 Super Generics Market for Oral Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.58 Super Generics Market for Subcutaneous Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.59 Super Generics Market for Intravenous Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.60 Super Generics Market for Other Routes of Administration in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.61 Super Generics Market for Small Molecule in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.62 Super Generics Market for Biologics in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.63 Super Generics Market for Complex Generics in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.64 Super Generics Market for Other Small Molecules in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.65 Super Generics Market for Prefilled Syringe in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.66 Super Generics Market for Vials in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.67 Super Generics Market for Aerosols in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.68 Super Generics Market for Tablets in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.69 Super Generics Market for Capsules in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.70 Super Generics Market for Other Type of Products in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.71 Supergeneric Drugs Market in Rest of the World, 2023-2035 (USD Billion)
Figure 13.72 Super Generics Market for Oncological Disorders in Rest of the World, 2023-2035 (USD Billion)
Figure 13.73 Super Generics Market for Metabolic Disorders in Rest of the World, 2023-2035 (USD Billion)
Figure 13.74 Super Generics Market for Neurological Disorders in Rest of the World, 2023-2035 (USD Billion)
Figure 13.75 Super Generics Market for Respiratory Disorders in Rest of the World, 2023-2035 (USD Billion)
Figure 13.76 Super Generics Market for Cardiovascular Disorders in Rest of the World, 2023-2035 (USD Billion)
Figure 13.77 Super Generics Market for Other Disorders in Rest of the World, 2023-2035 (USD Billion)
Figure 13.78 Super Generics Market for Oral Route of Administration in Rest of the World, 2023-2035 (USD Billion)
Figure 13.79 Super Generics Market for Subcutaneous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
Figure 13.80 Super Generics Market for Intravenous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
Figure 13.81 Super Generics Market for Other Routes of Administration in Rest of the World, 2023-2035 (USD Billion)
Figure 13.82 Super Generics Market for Small Molecule in Rest of the World, 2023-2035 (USD Billion)
Figure 13.83 Super Generics Market for Biologics in Rest of the World, 2023-2035 (USD Billion)
Figure 13.84 Super Generics Market for Complex Generics in Rest of the World, 2023-2035 (USD Billion)
Figure 13.85 Super Generics Market for Other Small Molecules in Rest of the World, 2023-2035 (USD Billion)
Figure 13.86 Super Generics Market for Prefilled Syringe in Rest of the World, 2023-2035 (USD Billion)
Figure 13.87 Super Generics Market for Vials in Rest of the World, 2023-2035 (USD Billion)
Figure 13.88 Super Generics Market for Aerosols in Rest of the World, 2023-2035 (USD Billion)
Figure 13.89 Super Generics Market for Tablets in Rest of the World, 2023-2035 (USD Billion)
Figure 13.90 Super Generics Market for Capsules in Rest of the World, 2023-2035 (USD Billion)
Figure 13.91 Super Generics Market for Other Type of Products in Rest of the World, 2023-2035 (USD Billion)
Figure 14.1 Concluding Remarks: Super Generics Drugs Market Landscape
Figure 14.2 Concluding Remarks: Super Generics Technologies Market Landscape
Figure 14.3 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 5.1 Different Nomenclatures Used for Value-added Generics
Table 5.2 Comparison of FDA Drug Approval Pathways
Table 5.3 Market Exclusivity Period for Different Submission Classifications
Table 5.4 Comparison of Drug Development Timeline
Table 6.1 Super Generic Drugs: List of FDA Approved Drugs, 2016-2024
Table 6.2 Super Generic Drugs: Additional Details, 2016-2024
Table 7.1 Super Generic Technologies: Information on Type of Drug Modification and Type of Technology
Table 7.2 Super Generic Technologies: Information on Type of Molecule, Route of Administration and Type of Value Addition
Table 7.3 Super Generic Technologies: List of Developers
Table 9.1 List of Profiled Supergeneric Technology Providers
Table 9.2 CritiTech (NanOlogy): Pipeline Overview
Table 9.3 CritiTech (NanOlogy): Recent Developments and Future Outlook
Table 9.4 Crossject: Pipeline Overview
Table 9.5 Crossject: Recent Developments and Future Outlook
Table 9.6 DelSiTech: Pipeline Overview
Table 9.7 DelSiTech: Recent Developments and Future Outlook
Table 9.8 Heron Therapeutics: Recent Developments and Future Outlook
Table 9.11 Mayne Pharma: Recent Developments and Future Outlook
Table 9.12 Neurelis: Pipeline Overview
Table 9.13 Taiwan Liposome Company: Pipeline Overview
Table 9.14 Taiwan Liposome Company: Recent Developments and Future Outlook
Table 10.1 Adverse Events Comparison: Austedo® versus Xenazine®
Table 10.2 Adverse Events Comparison: Abraxane® versus Taxol®
Table 10.3 Adverse Events Comparison: Procysbi® versus Cystagon®
Table 10.4 Adverse Events Comparison: Trokendi XR® versus Topiramate IR®
Table 11.1 Most Likely Candidates for Supergeneric Development
Table 11.2 Likely Candidates for Supergeneric Development
Table 11.3 Less Likely Candidates for Supergeneric Development
Table 11.4 Least Likely Candidates for Supergeneric Development
Table 15.1 Impact of Number of Drug Manufacturers on Price of Generic Drugs
Table 15.5 Historical Drug Development Costs
Table 15.6 Super Generic Drugs: Distribution by Route of Administration
Table 15.7 Super Generic Drugs: Distribution by Target Indication
Table 15.8 Super Generic Drugs: Distribution by Target Therapeutic Area
Table 15.9 Super Generic Drugs: Distribution by Submission Classification Code
Table 15.10 Most Active Players: Analysis by Number of Super Generic Drugs
Table 15.11 Super Generic Technologies: Distribution by Type of Drug Modification
Table 15.12 Super Generic Technologies: Distribution by Type of Technology
Table 15.13 Super Generic Technologies: Distribution by Type of Molecules
Table 15.14 Super Generic Technologies: Distribution by Route of Administration
Table 15.15 Super Generic Technologies: Distribution by Type of Value Addition
Table 15.16 Super Generic Technology Developers: Distribution by Year of Establishment
Table 15.17 Super Generic Technology Developers: Distribution by Company Size
Table 15.18 Super Generic Technology Developers: Distribution by Location of Headquarters (Region)
Table 15.20 Most Active Players: Distribution by Number of Super Generic Technologies
Table 15.26 Mayne Pharma: Annual Revenues, FY 2019- HI FY 2024 (USD Million)
Table 15.27 Taiwan Liposome Company: Annual Revenues, 2014-H1 2019 (NT$ Million)
Table 15.28 Revenue Comparison: Xenazine® versus Austedo® (USD Million)
Table 15.29 Annual Revenues: Abraxane® 2012-2018 (USD Million)
Table 15.30 Annual Revenues: Avycaz® 2015-2018 (USD Million)
Table 15.31 Annual Revenues: Procysbi® 2016-2018 (USD Million)
Table 15.32 Annual Revenues: Trokendi XR® 2013-2018 (USD Million)
Table 15.33 Supergeneric Drugs Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035):Base Scenario (USD Billion)
Table 15.34 Super Generics Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
Table 15.35 Super Generics Market: Distribution by Route of Administration, 2023 and 2035 (USD Billion)
Table 15.36 Super Generics Market: Distribution by Type of Molecule, 2023 and 2035 (USD Billion)
Table 15.37 Super Generics Market: Distribution by Type of Small Molecule, 2023 and 2035 (USD Billion)
Table 15.38 Super Generics Market: Distribution by Type of Product, 2023 and 2035 (USD Billion)
Table 15.39 Super Generics Market: Distribution by Geography, 2023 and 2035 (USD Billion)
Figure 15.40 Supergeneric Drugs Market in North America, 2023-2035 (USD Billion)
Table 15.41 Super Generics Market for Oncological Disorders in North America, 2023-2035 (USD Billion)
Table 15.42 Super Generics Market for Metabolic Disorders in North America, 2023-2035 (USD Billion)
Table 15.43 Super Generics Market for Neurological Disorders in North America, 2023-2035 (USD Billion)
Table 15.44 Super Generics Market for Respiratory Disorders in North America, 2023-2035 (USD Billion) (USDBillion)
Table 15.45 Super Generics Market for Cardiovascular Disorders in North America, 2023-2035 (USD Billion)
Table 15.46 Super Generics Market for Other Disorders in North America, 2023-2035 (USD Billion)
Table 15.47 Super Generics Market for Oral Route of Administration in North America, 2023-2035 (USD Billion)
Table 15.48 Super Generics Market for Subcutaneous Route of Administration in North America, 2023-2035 (USD Billion)
Table 15.49 Super Generics Market for Intravenous Route of Administration in North America, 2023-2035 (USDBillion)
Table 15.50 Super Generics Market for Other Routes of Administration in North America, 2023-2035 (USD Billion)
Table 15.51 Super Generics Market for Small Molecule in North America, 2023-2035 (USD Billion)
Table 15.52 Super Generics Market for Biologics in North America, 2023-2035 (USD Billion)
Table 15.53 Super Generics Market for Complex Generics in North America, 2023-2035 (USD Billion)
Table 15.54 Super Generics Market for Other Small Molecules in North America, 2023-2035 (USD Billion)
Table 15.55 Super Generics Market for Prefilled Syringe in North America, 2023-2035 (USD Billion)
Table 15.56 Super Generics Market for Vials in North America, 2023-2035 (USD Billion)
Table 15.57 Super Generics Market for Aerosols in North America, 2023-2035 (USD Billion)
Table 15.58 Super Generics Market for Tablets in North America, 2023-2035 (USD Billion)
Table 15.59 Super Generics Market for Capsules in North America, 2023-2035 (USD Billion)
Table 15.60 Super Generics Market for Other Type of Products in North America, 2023-2035 (USD Billion)
Table 15.61 Supergeneric Drugs Market in Europe, 2023-2035 (USD Billion)
Table 15.62 Super Generics Market for Oncological Disorders in Europe, 2023-2035 (USD Billion)
Table 15.63 Super Generics Market for Metabolic Disorders in Europe, 2023-2035 (USD Billion)
Table 15.64 Super Generics Market for Neurological Disorders in Europe, 2023-2035 (USD Billion)
Table 15.65 Super Generics Market for Respiratory Disorders in Europe, 2023-2035 (USD Billion)
Table 15.66 Super Generics Market for Cardiovascular Disorders in Europe, 2023-2035 (USD Billion)
Table 15.67 Super Generics Market for Other Disorders in Europe, 2023-2035 (USD Billion)
Table 15.68 Super Generics Market for Oral Route of Administration in Europe, 2023-2035 (USD Billion)
Table 15.69 Super Generics Market for Subcutaneous Route of Administration in Europe, 2023-2035 (USD Billion)
Table 15.70 Super Generics Market for Intravenous Route of Administration in Europe, 2023-2035 (USD Billion)
Table 15.71 Super Generics Market for Other Routes of Administration in Europe, 2023-2035 (USD Billion)
Table 15.72 Super Generics Market for Small Molecule in Europe, 2023-2035 (USD Billion)
Table 15.73 Super Generics Market for Biologics in Europe, 2023-2035 (USD Billion)
Table 15.74 Super Generics Market for Complex Generics in Europe, 2023-2035 (USD Billion)
Table 15.75 Super Generics Market for Other Small Molecules in Europe, 2023-2035 (USD Billion)
Table 15.76 Super Generics Market for Prefilled Syringe in Europe, 2023-2035 (USD Billion)
Table 15.77 Super Generics Market for Vials in Europe, 2023-2035 (USD Billion)
Table 15.78 Super Generics Market for Aerosols in Europe, 2023-2035 (USD Billion)
Table 15.79 Super Generics Market for Tablets in Europe, 2023-2035 (USD Billion)
Table 15.80 Super Generics Market for Capsules in Europe, 2023-2035 (USD Billion)
Table 15.81 Super Generics Market for Other Type of Products in Europe, 2023-2035 (USD Billion)
Table 15.82 Supergeneric Drugs Market in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.83 Super Generics Market for Oncological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.84 Super Generics Market for Metabolic Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.85 Super Generics Market for Neurological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.86 Super Generics Market for Respiratory Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.87 Super Generics Market for Cardiovascular Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.88 Super Generics Market for Other Disorders in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.89 Super Generics Market for Oral Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.90 Super Generics Market for Subcutaneous Route of Administration in Asia-Pacific, 2023-2035 (USDBillion)
Table 15.91 Super Generics Market for Intravenous Route of Administration in Asia-Pacific, 2023-2035 (USDBillion)
Table 15.92 Super Generics Market for Other Routes of Administration in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.93 Super Generics Market for Small Molecule in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.94 Super Generics Market for Biologics in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.95 Super Generics Market for Complex Generics in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.96 Super Generics Market for Other Small Molecules in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.97 Super Generics Market for Prefilled Syringe in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.98 Super Generics Market for Vials in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.99 Super Generics Market for Aerosols in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.100 Super Generics Market for Tablets in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.101 Super Generics Market for Capsules in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.102 Super Generics Market for Other Type of Products in Asia-Pacific, 2023-2035 (USD Billion)
Table 15.103 Supergeneric Drugs Market in Rest of the World, 2023-2035 (USD Billion)
Table 15.104 Super Generics Market for Oncological Disorders in Rest of the World, 2023-2035 (USD Billion)
Table 15.105 Super Generics Market for Metabolic Disorders in Rest of the World, 2023-2035 (USD Billion)
Table 15.106 Super Generics Market for Neurological Disorders in Rest of the World, 2023-2035 (USD Billion)
Table 15.107 Super Generics Market for Respiratory Disorders in Rest of the World, 2023-2035 (USD Billion)
Table 15.108 Super Generics Market for Cardiovascular Disorders in Rest of the World, 2023-2035 (USD Billion)
Table 15.109 Super Generics Market for Other Disorders in Rest of the World, 2023-2035 (USD Billion)
Table 15.110 Super Generics Market for Oral Route of Administration in Rest of the World, 2023-2035 (USD Billion)
Table 15.111 Super Generics Market for Subcutaneous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
Table 15.112 Super Generics Market for Intravenous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
Table 15.113 Super Generics Market for Other Routes of Administration in Rest of the World, 2023-2035 (USD Billion)
Table 15.114 Super Generics Market for Small Molecule in Rest of the World, 2023-2035 (USD Billion)
Table 15.115 Super Generics Market for Biologics in Rest of the World, 2023-2035 (USD Billion)
Table 15.116 Super Generics Market for Complex Generics in Rest of the World, 2023-2035 (USD Billion)
Table 15.117 Super Generics Market for Other Small Molecules in Rest of the World, 2023-2035 (USD Billion)
Table 15.118 Super Generics Market for Prefilled Syringe in Rest of the World, 2023-2035 (USD Billion)
Table 15.119 Super Generics Market for Vials in Rest of the World, 2023-2035 (USD Billion)
Table 15.120 Super Generics Market for Aerosols in Rest of the World, 2023-2035 (USD Billion)
Table 15.121 Super Generics Market for Tablets in Rest of the World, 2023-2035 (USD Billion)
Table 15.122 Super Generics Market for Capsules in Rest of the World, 2023-2035 (USD Billion)
Table 15.123 Super Generics Market for Other Type of Products in Rest of the World, 2023-2035 (USD Billion)on)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3M
  2. 3SBio
  3. Abon Pharmaceuticals
  4. Abraxis BioScience (a subsidiary of Celgene)
  5. Accord Healthcare 
  6. AcelRx Pharmaceuticals
  7. Aclaris Therapeutics
  8. Acorda Therapeutics
  9. Acrotech Biopharma
  10. ACS Dobfar
  11. Actavis (a subsidiary of Teva Pharmaceutical)
  12. Adamis Pharmaceuticals 
  13. ADDMEDICA
  14. ADIENNE
  15. Aegis Therapeutics 
  16. Ailex Pharmaceuticals
  17. Akorn 
  18. Alcon
  19. Alembic Pharmaceuticals
  20. Allergan
  21. ALRISE Biosystems
  22. Altaire Pharmaceuticals
  23. Altus Formulation
  24. Alyvant
  25. American Regent
  26. Amerigen Pharmaceuticals
  27. Amneal Pharmaceuticals
  28. ANI Pharmaceuticals
  29. Antares Pharma 
  30. Apotex
  31. Aprecia Pharmaceuticals
  32. Armstrong Pharmaceuticals
  33. Ascendia Pharmaceuticals
  34. Ascendis Pharma
  35. Assertio Therapeutics
  36. AstraZeneca
  37. Aurobindo Pharma 
  38. Avadel Pharmaceuticals
  39. Avanir Pharmaceuticals
  40. Avedro
  41. Avion Pharmaceuticals
  42. B. Braun
  43. Bausch & Lomb 
  44. Baxter
  45. Bayer
  46. BDD
  47. Belcher Pharmaceuticals
  48. Atox Bio
  49. Bharat Serums and Vaccines
  50. BioDelivery Sciences International
  51. Birdie Pharmaceuticals
  52. Bracco
  53. Braeburn
  54. Bristol-Myers Squibb
  55. BWX Technologies
  56. Celator Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals)
  57. Celgene
  58. Cellix Bio
  59. Celltrion Healthcare
  60. Chiesi Farmaceutici 
  61. Cintex
  62. Cipla
  63. CMP Pharma
  64. Cocoon Biotech
  65. Coeptis Pharmaceuticals
  66. Covis Pharma 
  67. Cristal Therapeutics
  68. CritiTech
  69. Crossject
  70. C-Tri
  71. Cycle Pharmaceuticals
  72. Dauntless Pharmaceuticals 
  73. DelNova Healthcare
  74. DelSiTech
  75. Desitin Pharma
  76. Dexcel Pharma
  77. DFB Pharmaceuticals 
  78. DisperSol Technologies
  79. Dr. Reddy's Laboratories
  80. Druggability Technologies
  81. EASYWELL BIOMEDICALS
  82. ECI Pharmaceuticals
  83. Edenbridge Pharmaceuticals
  84. ELPEN
  85. Emmaus Life Sciences
  86. Encore Dermatology
  87. EPI Health
  88. epinamics
  89. Eurohealth International
  90. Exela Pharma Sciences
  91. EyePoint Pharmaceuticals
  92. Eyevance Pharmaceuticals
  93. Ferring Pharmaceuticals 
  94. Flexion Therapeutics
  95. Foresee Pharmaceuticals
  96. Fresenius Kabi
  97. Galderma 
  98. General Atlantic
  99. Genus Lifesciences
  100. Gland Pharma 
  101. GlaxoSmithKline
  102. Glenmark Pharmaceuticals 
  103. GP Pharm
  104. Handa Pharmaceuticals
  105. Hanmi Pharmaceutical
  106. HANSAmed
  107. HealthCare Royalty Partners 
  108. Heron Therapeutics
  109. Hetero
  110. Horizon Therapeutics
  111. Hospira 
  112. HQ Speciality Pharma
  113. Hyundai Bioscience
  114. IBSA Institut Biochimique
  115. iCeutica
  116. Impax Laboratories
  117. Impel NeuroPharma
  118. Indivior 
  119. InfoRLife
  120. Ingenus Pharmaceuticals
  121. Insmed 
  122. INSYS Therapeutics
  123. Intec Pharma
  124. Integral BioSystems
  125. IntelGenx
  126. Intellipharmaceutics International
  127. Intersect ENT
  128. Inventia Healthcare
  129. Ironshore Pharmaceuticals
  130. Italfarmaco
  131. Jiangsu Hengrui Medicine
  132. Jixi Biotechnology 
  133. Johnson & Johnson 
  134. Jubilant DraxImage 
  135. Kala Pharmaceuticals 
  136. Kaleo
  137. Kashiv BioSciences
  138. KC Pharmaceuticals 
  139. KemPharm
  140. Keystone Nano
  141. KVK Tech
  142. Larken Laboratories
  143. LATITUDE Pharmaceuticals
  144. leon-nanodrugs
  145. LipoSeuticals
  146. Liquidia Technologies
  147. Lundbeck
  148. Lupin
  149. Macleods Pharmaceuticals
  150. Mallinckrodt Pharmaceuticals
  151. Mayne Pharma
  152. Medesis Pharma
  153. MedinCell
  154. Medline Industries
  155. Merck
  156. Meridian Medical Technologies 
  157. Micelle BioPharma
  158. Mikart
  159. Mipharm
  160. Mithra Pharmaceuticals
  161. MSN Laboratories
  162. Mylan
  163. Nanocopoeia
  164. NanoVelos
  165. Natco Pharma
  166. NAVINTA
  167. Neos Therapeutics
  168. Nesher Pharmaceuticals
  169. Neurelis
  170. Nexus Pharmaceuticals
  171. Northstar Medical Radioisotopes
  172. Norton (Waterford)
  173. Nostrum Laboratories
  174. NOVADAQ Technologies (a subsidiary of Stryker)
  175. Novatech
  176. Novel Laboratories
  177. Novocol Healthcare
  178. NX Development
  179. Ocular Therapeutix
  180. Opiant Pharmaceuticals
  181. Optinose
  182. Osmotica Pharmaceuticals
  183. Paddock Laboratories 
  184. Par Pharmaceutical
  185. Par Sterile Products (a subsidiary of Par Pharmaceutical)
  186. Pearl Therapeutics
  187. Perrigo
  188. Pfizer 
  189. Pharmadax
  190. PLx Pharma
  191. Praxair
  192. ProSolus
  193. Provepharm Life Solutions
  194. Raptor Pharmaceuticals
  195. Recordati
  196. Rempex Pharmaceuticals
  197. Rising Pharmaceuticals
  198. Rosemont Pharmaceuticals
  199. Roxane Laboratories (a subsidiary of Hikma Pharmaceuticals)
  200. Rubicon Research
  201. RxMP Therapeutics
  202. Sagent Pharmaceuticals
  203. Salvat 
  204. Sandoz 
  205. SCILEX Pharmaceuticals 
  206. SGN Nanopharma
  207. Shanghai Hengrui Pharmaceutical
  208. Silvergate Pharmaceuticals
  209. Solani Therapeutics 
  210. Sol-Gel Technologies
  211. Spear Pharmaceuticals 
  212. St. Renatus
  213. Sun Pharmaceutical
  214. Sunny Pharmtech
  215. Sunovion Pharmaceuticals
  216. Supernus Pharmaceuticals 
  217. Taiwan Liposome Company
  218. Taro Pharmaceuticals
  219. Teligent
  220. TerSera Therapeutics 
  221. tesa Labtec
  222. Teva Pharmaceutical
  223. TherapeuticsMD 
  224. Tiger Pharmaceuticals
  225. Titan Pharmaceuticals 
  226. Tolmar
  227. Torrent Pharmaceuticals
  228. Tris Pharma
  229. Upsher-Smith Laboratories
  230. US Biotest 
  231. Valeant Pharmaceuticals 
  232. West-Ward Pharmaceuticals
  233. Xellia
  234. X-GEN Pharmaceuticals
  235. Zydus Cadila

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com